Materials and methods
Study design
Our systematic review was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement [5].
The present systematic review has been registered in the PROSPERO international prospective registry of systematic reviews by the National
Institute of Health Research (NIHR). The registration number is PROSPERO 2023 CRD42023454705.
Search strategy
To identify relevant articles, we conducted an electronic database search using several databases: PubMed, Google Scholar, ClinicalTrials.gov,
Cochrane library to identify studies using key words and MeSH terms. The date of the last screening was November 26, 2024. Using the
advanced search tool on PubMed, the following combination of key words was used: ((endometriosis) OR (endometrioma)) AND (antioxidants)
AND (oxidative stress) AND (treatment). No filters or limits were used. Additionally, the search was conducted using MeSH terms
(endometriosis [MeSH Terms]) AND ((antioxidants[MeSH Terms]) AND (treatment [MeSH Terms]) AND (oxidative stress [MeSH Terms]).
The Cochrane Library electronic database search strategy was conducted. The combination of the search was as follows: ((endometriosis) OR
(endometrioma)) AND (antioxidants) AND (oxidative stress) AND (treatment). No filters or limits were used. MeSH terms were also screened
(MeSH descriptor: [Endometriosis] explode all trees and with qualifier(s): [antioxidants - MeSH]).
The search was also conducted in the ClinicalTrials.gov electronic database using an advanced search combination: endometriosis |
antioxidants.
Study selection
For search conducting and further screening COVIDENCE software was used. To ensure the quality and accuracy of the search results, two
investigators performed the search independently. After the initial search, all articles were reviewed based on their titles and abstracts. The full
texts of the studies that appeared to be appropriate according to their titles and abstracts were reviewed. Potential trials were also identified by
searching the reference lists of the eligible trials. We included randomized (RCTs) and non-randomized clinical trials. Only articles written in
Manuscript accepted for publication
English were included. Abstracts from congresses and unpublished articles were not included. As this is a review of published studies,
Institutional Review Board (IRB) approval was not sought.
Two investigators (E.N., I.S) independently read the full texts of the preselected articles to verify their eligibility. Any studies with duplicate
records were excluded. To minimize potential bias during the review process, any disagreements about the inclusion or exclusion of
preselected studies were resolved with the help of a third author (A.L).
Inclusion criteria
The inclusion criteria specified autograft endometriosis mice or rat models and women with endometriosis related infertility, receiving
antioxidant therapy.
Studies that described high levels of oxidative stress markers due to non endometriosis-related reasons, phytoalexins, antioxidant decoctions
as a therapy were excluded.
Data Extraction and quality assessment
The studies included were independently collected by two authors (E.N., I.S) using a standardized data extraction procedure. We obtained the
following characteristics from our studies: study design, type of animal model, types of antioxidants and regimens used, and the number of
patients in each groups and the follow-up duration.
The analysis in animal models was aimed to evaluate the level of oxidative stress markers, embryo and oocyte quality, implant weight, volume
and histological cell scores of endometriotic lesions after antioxidant therapy
The analysis of human studies was aimed to establish the pregnancy outcomes in addition to previously mentioned parameters.
Risk of bias was assessed for each included study using the Cochrane Handbook for Systematic Reviews of Interventions [6]. Two reviewers
(V.T., A.L) independently assessed the quality of the selected studies. A third investigator (L.P) was involved in the case of inconsistencies. In
accordance with the Cochrane Handbook for Systematic Reviews of Interventions, the RoB 2 tool [7] was used to assess the risk of bias for
randomized controlled trials and ROBINS-I [8] for non-randomized trials, SYRCLE’s RoB tool for animal model studies [9].
Results
Summary of Included Studies
The study selection process is illustrated by the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow chart
diagram (Figure 1).
Manuscript accepted for publication
A total of 512 publications were identified through an electronic database search of PubMed, Google Scholar, and ClinicalTrials.gov., Cochrane
library.
Of these, 425 studies were screened for title and abstract. 388 were excluded, 38 were selected for eligibility assessment. After screening the
full-text articles, 27 were excluded for failing to meet the eligibility criteria. The references of the selected studies were additionally searched for
other eligible studies and 7 studies were identified. Finally, 11 trials that met the criteria were included in the systematic review. A total of 73
rats, 14 mice and 759 women from ten trials were analyzed. The detailed summary of the studies analysis is shown in Table 1-2.
Antioxidants effectiveness in animal population
In 4 studies, endometriosis was induced by transplanting autologous uterine tissue onto the peritoneal wall of female Wistar albino rats [10,11]
and female NMRI mice [12,13].
The vitamin C effectiveness in animal population
Ozlem Ulas Erten et al [10] and Yildirim Durak et al [11] evaluated the efficacy of vitamin C in the prevention and regression of endometriotic
implant development in an experimentally induced autografted endometriosis rat model. Implant weight and volume, histological cell scores and
trichrome fibrosis scores were measured. Both authors suggest that histological scores are independent of vitamin C dosage, in contrast to
implant volume. However, the exact reason for their insensitivity is not mentioned. It could either be due to the small number of animals
included or the lack of direct effects.
Hayedeh Hoorsan et al [12] conducted a study on the efficacy of vitamin C endometriosis treatment in the NMRI mouse model. In contrast to
the previous two studies, the authors found a significant difference not only in the volume of endometriotic implants but also in the trichrome
fibrosis scores (p=0.03). Follicle, atretic follicle and corpus luteum counts were also measured. The number of follicles was significantly
increased (p=0.0005) and the number of atretic follicles was significantly decreased (p=0.006) after vitamin C therapy.
L-arginine, L-carnitine effectiveness in animal population
The other study based on the induced endometriosis mouse model was conducted by Eshrat Kalehoei et al [13]. The authors compared the
effects of L-arginine (LA), L-carnitine (LC), bone morphogenetic stem cells (BMSC-CM) on endometriosis-induced oocyte quality and levels of
oxidative stress markers. In the endometriosis group, mice treated with LC, LA or BMSC-CM had significantly lower levels of oxidative stress
markers compared to control. In normal and endometriosis treatment groups In vitro fertilisation (IVF), cleavage and blastocyst formation rates
were significantly improved compared to the control (p < 0.05).
Antioxidants effectiveness in human population
Other 7 studies were based on the follicular fluid and plasma samples collected from women with endometriosis related infertility.
The vitamin C effectiveness in human population
Manuscript accepted for publication
In human population, the efficacy of vitamin C supplementation was analyzed by Xiang Lu et al [14]. There was no significant difference in
fertilization, implantation and pregnancy rates between all participants. The number of oocytes and frozen embryos in endometriosis groups
was significantly lower than in control (P<0.05). Treatment with vitamin C for 2 months improved its serum and follicular fluid concentration in
patients with endometriosis, however did not affect oxidative stress markers rate. The results could be as follows because of several limitations:
small sample size and only one time point measurement (2 months of vitamin C supplementation): comparison of different time points was not
performed.
N-acetyl-cysteine, L-carnitine effectiveness in human population
Vanessa S. I. et al. conducted two studies [15,16] in which the percentage of meiotically normal oocytes in metaphase II, presumptive zygotes,
cleavage rate, blastocyst formation rate and hatching rate were measured. The number of meiotically abnormal and normal metaphase II
oocytes was similar in all 9 groups. The authors suggest that follicular fluid (FF) from infertile women with endometriosis increases the
percentage of meiotically abnormal oocytes. There was no significant difference between groups in cleavage (p=0.54) and blastocyst formation
(p=0.4349) rates. However, the hatching rate was higher in the control follicular fluid group than in the endometriosis follicular fluid (EFF) group.
The addition of antioxidants in CFF groups did not affect the hatching rate. The addition of N-acetylcysteine reduces the destructive effects of
FF on the oocyte meiotic spindle and increases hatching rate. The addition of L-carnitine completely prevents this destructive effect on the
meiotic spindle, but is less effective in terms of hatching rate.
The vitamin C and vitamin E combination effectiveness in human population.
The effect of combined vitamin C + vitamin E treatment was evaluated by Jennifer Mier-Cabrera et al [17], Nalini Santanam et al [18] and Leila
Amini et al [19].
Jennifer Mier-Cabrera et al [17] analyzed the lipid hydroperoxide (LOOH) and malondialdehyde (MDA) rate in plasma and peritoneal fluid.
There was a statistically significant difference in plasma LOOH and MDA concentrations between control and treatment groups. Leila Amini et
al [19] held randomized, triple-blind placebo-controlled clinical trial, where statistically reduced MDA (p=0.002) and reactive oxygen species
(ROS) (p < 0.001) levels in treatment group compared to placebo were evaluated.
Anti- myeloperoxidase therapy human population
Nalini Santanam et al [18] suggested that the level of myeloperoxidase (MPO) - one of the oxidative stress markers - depends on the severity
of endometriosis. Mean MPO levels in follicular fluid collected from women with severe endometriosis were significantly higher than in control
and mild endometriosis groups. Combination antioxidant treatment did not significantly reduce MPO levels in both groups.
Astaxanthin therapy in human population
Sahar Rostami et al. conducted a study on the efficacy of astaxanthin (AST) on oxidative stress markers, cytokine levels and associated
reproductive technology (ART) outcomes in infertile women with endometriosis [20]. All parameters were reduced after antioxidant therapy
Manuscript accepted for publication
except serum catalase (CAT), IL-1b, IL-6 levels. Embryo quality, number of metaphase II oocytes improved significantly after therapy. However,
the number of embryos transferred, fertilisation rate and pregnancy rate were similar in both groups.
Visualisation tools were provided by the ROBVIS application [21]. According to the ROBINS-I tool, the overall risk of bias for non-randomised
trials was 66,7 % low and 33,3% serious (Figure 2). Based on the RoB 2 tool (Figure 3), randomized trials had a 75% chance of low risk of bias
and an 25% chance of some concern regarding the overall risk of bias. The SYRCLE’s RoB tool was used to assess the quality of included
animal studies (Figure 4). The risk of allocation concealment and random housing could not be confirmed because none of the studies offered
complete information.
Discussion
There is increasing evidence to suggest that specific diet patterns and nutrients may modulate the pathophysiological processes underlying
endometriosis.
In this systematic review, we evaluated the efficiency of antioxidants supplementation in endometriosis treatment. We found out that
antioxidants reduce the severity of endometriosis symptoms by affecting the pathogenesis of the disease.
Oxidative stress occurs when the balance between reactive oxygen species production and antioxidant capacity is disturbed, either by
insufficient antioxidant protection or by increased ROS production. The relationship between ROS production and the progression of
endometriosis has been studied previously [22]. Due to dysregulation of iron metabolism, these abnormal endometriotic lesions are thought to
be resistant to ferroptosis. Ferroptosis is a form of regulated, iron-catalyzed cell death caused by excessive lipid peroxidation in cell
membranes. This process was first described by Dixon in 2012 [23].
Li B et al [24] found out that there was an excess expression of ferroptosis-associated genes in the ectopic and eutopic endometrium in
patients with endometriosis, showing a general trend towards inhibition of the ferroptosis pathway. Increased transferrin receptors (TFR1) and
Ras gene mutations in abnormal endometriotic cells directly affect ferroptosis resistance. A local imbalance in iron homeostasis leads to
oxidative stress in the intraperitoneal cavity, inflammation and ferroptosis in intact peripheral tissues. Iron-dependent ROS synthesis is based
on the Fenton reaction: Fe2+ + H2O2 → Fe3+ + OH- + OH-. As a result, a hydroxyl radical (-OH) is formed, leading to lipid peroxidation and
accumulation of lipid LOOH, which damages the membrane. This is why ectopic endometriotic tissue has higher levels of lipid peroxidation
products than normal endometrial tissue. This is also confirmed by other studies [17, 25].
In addition, we observe changes in enzyme levels - SOD and indicators such as TAC, TOS and OSI in serum and FF. The decrease in TAC and
SOD between patients with and without endometriosis is confirmed. It is noted that there was a significant difference in this indicator in FF as
opposed to serum between both groups [14]. Total antioxidant response (TAR) is also lower in patients with endometriosis, leading to an excess
of OSI [26]. Treatment with AST improved TAC and SOD levels [19]. LC and LA administration also improved the TAC, reduced TOS, NO and
OSI (P<0.05) [16]. However, vitamin C treatment showed no difference in oxidative stress markers and enzyme levels [14]. But there is
evidence that vitamin C prevents the progression of endometriotic lesion development by reducing their weight, size and volume [10-12].
Manuscript accepted for publication
Vitamin C and vitamin E combination significantly suppressed levels of MPO (a neutrophil marker that is increased due to oxidative stress and
depends on the severity of endometriosis) in FF [18]. These findings support previous data [26].
It should be mentioned that immune cells play a crucial role in ectopic endometriotic lesions detection and elimination. It is known that
oxidative stress impairs the efficiency of the immune system, leading to reduced recognition of abnormal endometrial tissue, allowing its
invasion, accumulation and growth in the pelvic and abdominal cavity. Antioxidants are known to stimulate the whole process of phagocytosis
[27]. Yildirim Durak et al [11] found that NK cell (Natural killer cells) levels were significantly lower in control groups than in those on antioxidant
therapy (P < 0.01). Similar results have been reported in other studies [28,29]. It should be noted that the decrease in cellular immunity
correlates with the severity of the disease. Whether this decrease in NK cells is a cause or a consequence of the severity of endometriosis
remains unclear. The reduction in cellular immunity is related to the "endometriotic disease theory", also known as Sampson's theory, according
to which the most important factor in the development of endometriosis is not the initial implantation in the peritoneal cavity, but cell mutations
that cannot be eliminated due to the reduced number of immune cells. It is these ectopic endometriotic cells, ignored by regulatory factors in
the peritoneal fluid, that trigger the disease [30].
All of the above factors affect fertility in women with endometriosis. The granulosa cells and the surrounding cumulus cells in the follicle are
involved in the maturation of the oocyte. This process depends on the intrafollicular environment. If it is damaged, the developmental
competence of the oocytes, the quality of the embryos and the clinical pregnancy rate are reduced. In the case of antioxidant therapy, IVF,
cleavage and blastocyst formation rates are increased compared to no treatment. It is also important to highlight that this finding is potentially
helpful for translation into clinical practice [13-16,19]. High-level antioxidant diet can significantly influence inflammatory processes, which are
directly related to the pathophysiology of endometriosis.
Strengths and limitations of the study
The limitations we encountered were mainly related to the available data sources. The patients were not similar between studies: rats and mice
with induced endometriosis, human. The heterogeneity of the antioxidants should also be mentioned. A total of 6 antioxidants were included in
this review, but it is difficult to compare them because of differences in regimen and dosage in each study. Studies in animal models have a
lower quality of evidence than those in humans. It is important to emphasize that more research is needed in human to assess the clinical
relevance and to establish the efficacy of antioxidants, as clinical trials evaluating their effects on endometriosis are still relatively limited.
The main strength of this study is that we observed antioxidant supplementation as a therapy that affect oxidative stress – the main aspect of
endometriosis pathogenesis. All previously published reviews were aimed to analyze the types of oxidative stress markers and their levels in
patients with endometriosis, but did not observe and summarize any medications for their reduction.
Implications for future studies may include investigating the development of targeted antioxidant treatment, the possibility of delivering
antioxidants directly to endometriotic lesions. This could potentially increase the efficacy of antioxidant therapy and minimize potential side
effects.
Manuscript accepted for publication
References
[1] Czyzyk A, Podfigurna A, Szeliga A, Meczekalski B. Update on endometriosis pathogenesis. Minerva Ginecol. 2017;69(5):447–461.
doi:10.23736/S0026-4784.17.04048-5.
[2] Ng SW, Norwitz SG, Taylor HS, Norwitz ER. Endometriosis: The role of iron overload and ferroptosis. Reprod Sci. 2020;27(7):1383–1390.
doi:10.1007/s43032-020-00164-z.
[3] Kobayashi H, Yoshimoto C, Matsubara S, Shigetomi H, Imanaka S. Current understanding of and future directions for endometriosis-related
infertility research with a focus on ferroptosis. Diagnostics (Basel). 2023;13(11):1926. doi:10.3390/diagnostics13111926.
[4] Kao SH, Huang HC, Hsieh RH, Chen SC, Tsai MC, Tzeng CR. Oxidative damage and mitochondrial DNA mutations with endometriosis. Ann
NY Acad Sci. 2005;1042:186–194. doi:10.1196/annals.1338.021.
[5] Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance
and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. doi:10.1136/bmj.n160.
[6] Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions version
6.1 (updated September 2020). Cochrane, 2020. Available from: www.training.cochrane.org/handbook.
[7] Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomized
trials. BMJ. 2019;366:l4898.
[8] Sterne JAC, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in
nonrandomized studies of interventions. BMJ. 2016;355:i4919.
[9] Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE's risk of bias tool for animal studies.
BMC Med Res Methodol. 2014;14:43. doi:10.1186/1471-2288-14-43.
[10] Erten OU, Ensari TA, Dilbaz B, Cakiroglu H, Altinbas SK, Çaydere M, et al. Vitamin C is effective for the prevention and regression of
endometriotic implants in an experimentally induced rat model of endometriosis. Taiwan J Obstet Gynecol. 2016;55(2):251–257.
doi:10.1016/j.tjog.2015.07.004.
[11] Durak Y, Kokcu A, Kefeli M, Bildircin D, Çelik H, Alper T. Effect of vitamin C on the growth of experimentally induced endometriotic cysts. J
Obstet Gynaecol Res. 2013;39(7):1253–1258. doi:10.1111/jog.12050.
[12] Hoorsan H, Simbar M, Tehrani FR, Fathi F, Mosaffa N, Riazi H, et al. The effectiveness of antioxidant therapy (vitamin C) in an
experimentally induced mouse model of ovarian endometriosis. Womens Health (Lond). 2022;18:17455057221096218.
doi:10.1177/17455057221096218.
Manuscript accepted for publication
[13] Kalehoei E, Moradi M, Azadbakht M, Zhaleh H, Abadi SAL, Mahdiuni H, et al. Therapeutic effects of L-arginine, L-carnitine, and
mesenchymal stem cell-conditioned medium on endometriosis-induced oocyte poor quality in an experimental mouse model. J Obstet
Gynaecol Res. 2023;49(4):1180–1188. doi:10.1111/jog.15569.
[14] Lu X, Wu Z, Wang M, Cheng W. Effects of vitamin C on the outcome of in vitro fertilization-embryo transfer in endometriosis: A randomized
controlled study. J Int Med Res. 2018;46(11):4624–4633. doi:10.1177/0300060518786918.
[15] Giorgi VS, Da Broi MG, Paz CC, Ferriani RA, Navarro PA. N-acetyl-cysteine and l-carnitine prevent meiotic oocyte damage induced by
follicular fluid from infertile women with mild endometriosis. Reprod Sci. 2016;23(3):342–351. doi:10.1177/1933719115602772.
[16] Giorgi VSI, Ferriani RA, Navarro PA. Follicular fluid from infertile women with mild endometriosis impairs in vitro bovine embryo
development: Potential role of oxidative stress. Rev Bras Ginecol Obstet. 2021;43(2):119–125. doi:10.1055/s-0040-1718443.
[17] Mier-Cabrera J, Genera-García M, De la Jara-Díaz J, Perichart-Perera O, Vadillo-Ortega F, Hernández-Guerrero C. Effect of vitamins C
and E supplementation on peripheral oxidative stress markers and pregnancy rate in women with endometriosis. Int J Gynaecol Obstet.
2008;100(3):252–256. doi:10.1016/j.ijgo.2007.08.018.
[18] Santanam N, Zoneraich N, Parthasarathy S. Myeloperoxidase as a potential target in women with endometriosis undergoing IVF. Reprod
Sci. 2017;24(4):619–626. doi:10.1177/1933719116667225.
[19] Amini L, Chekini R, Nateghi MR, Haghani H, Jamialahmadi T, Sathyapalan T, et al. The effect of combined vitamin C and vitamin E
supplementation on oxidative stress markers in women with endometriosis: A randomized, triple-blind placebo-controlled clinical trial. Pain Res
Manag. 2021;2021:5529741. doi:10.1155/2021/5529741.
[20] Rostami S, Alyasin A, Saedi M, Nekoonam S, Khodarahmian M, Moeini A, et al. Astaxanthin ameliorates inflammation, oxidative stress,
and reproductive outcomes in endometriosis patients undergoing assisted reproduction: A randomized, triple-blind placebo-controlled clinical
trial. Front Endocrinol. 2023;14:1144323. doi:10.3389/fendo.2023.1144323.
[21] McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias
assessments. Res Syn Meth. 2020;12(1):55–617. doi:10.1002/jrsm.1411.
[22] Scutiero G, Iannone P, Bernardi G, Bonaccorsi G, Spadaro SA, Volta CA, et al. Oxidative stress and endometriosis: A systematic review of
the literature. Oxid Med Cell Longev. 2017;2017:7265238. doi:10.1155/2017/7265238.
[23] Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: An iron-dependent form of nonapoptotic cell
death. Cell. 2012;149(5):1060–1072. doi:10.1016/j.cell.2012.03.042.
[24] Li B, Duan H, Wang S, Li Y . Ferroptosis resistance mechanisms in endometriosis for diagnostic model establishment. Reprod Biomed
Online. 2021;43(1):127–138. doi:10.1016/j.rbmo.2021.04.002.
Manuscript accepted for publication
[25] de Lima CB, Cordeiro FB, Camargo M, Zylbersztejn DS, Cedenho AP , Bertolla RP, et al. Follicular fluid lipid peroxidation levels in women
with endometriosis during controlled ovarian hyperstimulation. Hum Fertil (Camb). 2017;20(1):48–54. doi:10.1080/14647273.2016.1246753.
[26] ODF, Waelkens E, Peterse DP , Lebovic D, Meuleman C, Tomassetti C, et al. Evaluation of total, active, and specific myeloperoxidase
levels in women with and without endometriosis. Gynecol Obstet Investig. 2018;83(2):133–139. doi:10.1159/000475664.
[27] Assaf L, Eid AA, Nassif J. Role of AMPK/mTOR, mitochondria, and ROS in the pathogenesis of endometriosis. Life Sci. 2022;306:120805.
doi:10.1016/j.lfs.2022.120805.
[28] Fan D, Wang X, Shi Z, Jiang Y, Zheng B, Xu L, et al. Understanding endometriosis from an immunomicroenvironmental perspective. Chin
Med J (Engl). 2023;136(16):1897–1909. doi:10.1097/CM9.0000000000002649.
[29] Wang L, Li L, Li Y, Huang C, Lian R, Wu T, et al. History of endometriosis is associated with decreased peripheral NK cytotoxicity and
increased infiltration of uterine CD68+ macrophages. Front Immunol. 2021;12:711231. doi:10.3389/fimmu.2021.711231.
[30] Chen S, Liu Y , Zhong Z, Wei C, Liu Y , Zhu X. Peritoneal immune microenvironment of endometriosis: Role and therapeutic perspectives.
Front Immunol. 2023;14:1134663. doi:10.3389/fimmu.2023.1134663.
Manuscript accepted for publication
Table 1. Description of selected studies included in the review (rats and mice)
First author, year
of publication
Title Population Follow up
period
Intervention Comparison Outcomes
Ozlem Ulas Erten
et al., 2016
[10]
Vitamin C is effective for
the prevention and
regression of
endometriotic implants in
an experimentally induced
rat model of endometriosis
Female Wistar Albino Rats
(n=33)
Weight=209g-270g
A group (n=11)
B group (n=11)
C group (n=11)
42 days Surgical induced endometriosis
(autograft model)
A group: 1
st operation + intravenous
vitamin C 500mg/kg every 2 days
B group: 1st operation; 2nd operation +
intravenous vitamin C 500 mg/kg every 2
days
C group (1st operation; 2nd operation)
Vitamin C vs no
vitamin C
in all groups
Implant volume at the 2nd operation (mm3)
Implant volume at the 3rd operation (mm3)
Weight 1 (initial) (g)
Weight 2 (final) (g)
Histological cell scores
Trichrome fibrosis scores
Yildirim Durak et
al., 2013
[11]
Effect of vitamin C on the
growth of experimentally
induced endometriotic
cysts.
Female Wistar Albino Rats
(n=40)
V1 group (n=10)
V2 group (n=10)
V3 group (n=10)
C group (n=10)
6 weeks Surgical induced endometriosis
(autograft model)
V1 group: 0.5 mg (2mg/kg) vit C/1 mL
water for 6 weeks
V2 group: 1.25 mg (5 mg/kg) vit C/1 mL
water for 6 weeks
V3 group: 2.5 mg (10 mg/kg) vit C/1 mL
water for 6 weeks
C group: distillated water 1 mL for 6 weeks
Final surgical assessment
Vitamin C vs no
vitamin C in all
groups
Implant volume after opertaion (mm3)
Weight of cyst (mg)
Histological cell scores
Trichrome fibrosis scores
NK cell contents
Eshrat Kalehoei
et al., 2023
[13]
Therapeutic effects of L-
arginine, L-carnitine, and
mesenchymal stem cell-
conditioned medium on
endometriosis-induced
oocyte poor quality in an
Adult female NMRI mice (6–
8 weeks old).
(n=not stated)
1. EMS induction
2. IVF
1. control
2. 250 mg/kg LA
3. 250 mg/kg LC
1. In vitro maturation of immature oocytes:
GV (%)
Manuscript accepted for publication
experimental mouse
model
1. Normal group
2. EMS-induced group
LA: 250 mg/kg
LC: 250 mg/kg LC
BMSC-CM: 100 μL of CM/mouse
4. 100 μL BMSC-
CM
GVBD (%)
MII (%)
DEG (%)
2. Blastocysts cell number
N. Blast
N. total cells
N. TE
N. ICM
TE/ICM
3. The percentage of different steps of mice emb
development
N. MII
IVF (%)
Cleavage (%)
Morula (%)
Blastocyst (%) Degenerated (%)
4. blood serum antioxidant capacity
TAC (nmol/mL)
NO (nmol/mL)
TOS (nmol/mL)
OSI
All these outcomes are assessed in both EMS a
normal groups and according to different antioxi
therapy (CO, LA, LC, BMSC-CM).
Manuscript accepted for publication
Hayedeh
Hoorsan et al.,
2022
[12]
The effectiveness of
antioxidant therapy
(vitamin C) in an
experimentally induced
mouse model of ovarian
endometriosis
Mature, virgin female NMRI
mice (n=14)
A group (n=7)
B group (n=7)
Not stated Surgical induced endometriosis
(autograft model)
2
nd surgery (assessment of the
endometriotic implants)
A group: 50 mg/kg (0.5 mL) vit C every 2
days for 4 weeks
B group: a 0.5 mL mix of water and starch
Final surgical assessment
Vitamin C vs no
vitamin C
in all groups
Implant volume at the 2nd operation (mm3)
Implant volume at the 3rd operation (mm3)
Weight 1 (initial) (g)
Weight 2 (final) (g)
Histological cell scores
Trichrome fibrosis scores
Follicle number
Atretic follicle number
Corpus luteum number
Abbrevations: NK, natural killer; vit C, vitamin C, EMS, endometriosis; IVF, in vitro fertilization; LA, L-arginine; LC, L-carnitine; BMSC-CM, bone
morphogenetic stem cells GV: Germinal vesicle; GVBD: Germinal vesicle break down; MII, metaphase II; DEG: degenerate oocytes; GVBD:
Germinal vesicle break down; TOS, total oxidant status; NO, nitric oxide; TAC, total antioxidant capacity; OSI, oxidative stress index; CO,
control.
Manuscript accepted for publication
Table 2. Description of selected studies included in the review (patients - human)
First
author,
year of
publication
Title Population Follow up
period
Intervention Comparison Outcomes
Vanessa
S. I. et al.,
2015
[15]
N-Acetyl-
Cysteine and L-
Carnitine
Prevent Meiotic
Oocyte Damage
Induced by
Follicular Fluid
From Infertile
Women With
Mild
Endometriosis
FF samples from
infertile women
(n=22)
1. EMS-
associated
infertility (n=11)
2. other infertility
(n=11)
February
2009 -
February
2011
1. Laparoscopic
surgery in women
with EMS.
2. FF-collection
3. Bovine oocyte
collection
4. In Vitro Maturation
1.NAC 1.5 mmol/L
2. LC 0.6 mg/mL
3.NAC 1.5 mmol/L +
LC 0.6 mg/mL
1. (No-FF)
2. (CFF)
3. (C +
NAC 1.5
mmol/L)
4. (C + LC
0.6 mg/mL)
5. (C +
2Ao);
6. (EFF)
7. (E + NAC
1.5 mmol/L)
8. (E + LC
0.6 mg/mL)
9. (E +
2Ao).
MI, n (%)
TI, n (%)
PA, n (%)
Total no. of
MII, n (%)
Analyzable
MII, n (%)
Normal MII, n
(%)
Vanessa
S. I. et al.,
2021
[16]
Follicular Fluid
from Infertile
Women with
Mild
Endometriosis
Impairs In Vitro
Bovine Embryo
Development:
FF samples from
infertile women
(n=22)
February
2009 -
February
2011
1. Laparoscopic
surgery in women
with EMS.
2. FF-collection
3. Bovine oocyte
collection
1. (No-FF)
2. (CFF)
3. (C +
NAC 1.5
mmol/L)
Presumptive
zygotes (n)
Cleavage rate
% (n)
Manuscript accepted for publication
Potential Role of
Oxidative Stress
1. EMS-
associated
infertility (n=11)
2. other infertility
(n=11)
4. In Vitro Maturation
5. In Vitro
Fertilization
6. n Vitro Embryo
Culture
1.NAC 1.5 mmol/L
2. LC 0.6 mg/mL
3.NAC 1.5 mmol/L +
LC 0.6 mg/mL
4. (C + LC
0.6 mg/mL)
5. (C +
2Ao);
6. (MEFF)
7. (MEFF +
NAC 1.5
mmol/L)
8. (MEEF +
LC 0.6
mg/mL)
9. (MEFF +
2Ao).
Blastocysts
formation rate
% (n)
Hatching rate
% (n)
Xiang Lu
et al.,
2018
[14]
Effects of
vitamin C on the
outcome of in
vitro fertilization–
embryo transfer
in endometriosis:
A randomized
controlled study
Patients with
EMs (n=280)
Group 1
– Vit C
treatment
(n=160)
Group 2
– no vit C
(n=120)
Patients with no
EMs (n=150)
June 2013
-
December
2016.
1. IVF-ET procedure
2. Vit. C treatment
Group 1 (n=160)
received 1000
mg/day from 2
months before IVF-
ET treatment until 2
weeks after ET
EMS
patients vs
no EMS
patients.
EMS
patients
treated with
vit C/ not
treated with
vit C
1. Laboratory
and pregnancy
outcomes in
EMS patients/
no EMS
patients
Total Gn
dosage
No. of
retrieved
oocytes
Fertilization
rate (%)
High-grade
embryo rate
(%)
Manuscript accepted for publication
Implantation
rate (%)
Clinical
pregnancy rate
(%)
No. of frozen
embryos
2. Changes in
serum levels
of VitC and
oxidative
stress markers
in EMS
patients with
vit C/ no vit C
Serum levels
of VitC
(μmol/L)
Serum levels
of SOD (U/L)
Serum levels
of
TAC(mmol/L)
Serum levels
of MDA(μM)
Serum levels
of ROS(cps)
Manuscript accepted for publication
Jennifer
Mier-
Cabrera et
al., 2008
[17]
Effect of
vitamins C and E
supplementation
on peripheral
oxidative stress
markers and
pregnancy rate
in women with
endometriosis
Patients with
EMs (n=34)
Group 1 – Vit C
and Vit E
treatment (n=16)
Group 2 –
placebo (n=18)
15 months Group 1 - 343 mg of
vitamin C and 84 mg
of vitamin E
Vit C and vit
E patints
group vs
placebo
group
1. Oxidative
stress marker
levels in
women with
endometriosis
((Baseline, at
2 months, at 4
months, at 6
months in PF,
plasma).
LOOH
(μmol/L)
MDA (μmol/L)
2. Pregnancy
rate
Nalini
Santanam
et al.,
2016
[18]
Myeloperoxidase
as a Potential
Target in
Women With
Endometriosis
Undergoing IV
Patients (n=117)
Complete data
(n=68).
No EMs group
(n=41)
Mild EMs group
(n=20)
Not stated 1. IVF
2. Collection of FF
3. Collection of
Blood Plasma
Patients received
800 IU of vit E and
1000 IU of vit C for a
minimum of 8 weeks:
Vit C and vit
E patints
group vs
placebo
group
MPO level
(ng/ml)
Manuscript accepted for publication
Moderate/severe
EMs group (n=7)
No EMs group vit
C+E (n=5)
Mild EMs group vit
C+E (n=5)
Moderate/severe
EMs group vit C+E
(n=4)
Sahar
Rostami et
al., 2023
[20]
Astaxanthin
ameliorates
inflammation,
oxidative stress,
and reproductive
outcomes in
endometriosis
patients
undergoing
assisted
reproduction: A
randomized,
triple-blind
placebo-
controlled
clinical trial
Infertile patients
(n=73) with
EMs.
Complete data
(n=50).
AST group
(n=25)
Placebo group
(n=25)
December
2021 -
September
2022.
1. IVF
2. Blood and FF
collection
AST group: 6 mg
daily of oral AST for
12 weeks
Placebo group: 6 mg
daily of placebo
capsules for 12
weeks
AST
treatment
vs placebo
1. OS markers
and cytokine
levels
MDA
SOD
CAT
TAC
L-1b
IL-6
TNF-a
2. ART
outcomes
Manuscript accepted for publication
Number of
oocytes
GV
MI
MII
Oocyte
maturity rate
(MII %)
Fertilized
Fertilization
rate (%)
Number of
frozen
embryos
High-quality
embryos
Frozen
embryos
Number of
transferred
embryos
Manuscript accepted for publication
Leila
Amini et
al., 2021
[19]
The Effect of
Combined
Vitamin C and
Vitamin E
Supplementation
on Oxidative
Stress Markers
in Women with
Endometriosis: A
Randomized,
Triple-Blind
Placebo-
Controlled
Clinical Trial
Patients with
endometriosis
(n=60)
A group (n=30)
B group (n=30)
June 2017
-
November
2017
A group: vitamin C
1000 mg/day (2
tablets/500 mg) +
vitamin E 800 IU/day
(2 tablets/400 IU) for
8 weeks.
B group (placebo
pills (mannitol and
magnesium stearate
polyvinylpyrrolidone))
for 8 weeks.
Vit C and vit
E patints
group vs
placebo
group
1. OS markers
levels
MDA
ROS
TAC
2. VAS score
of
dysmenorrhea,
dyspareunia
Abbrevations: CFF, control follicular fluid; OS, oxidative stress; ROS, reactive oxygen species; LC, L-carnitine; NAC, N-Acetyl-Cysteine; BMSC-
CM, bone morphogenetic stem cells; TOS, total oxidant status; NO, nitric oxide; TAC, total antioxidant capacity; OSI, oxidative stress index;
IVF, In vitro fertilization; SOD, superoxide dismutase; MDA, malondialdehyde; FF, follicular fluid; EFF, endometriosis follicular fluid; CFF, control
follicular fluid; LOOH, lipid hydroperoxide; MPO, myeloperoxidase; AST, astaxanthin; ART, associated reproductive technology; CAT, catalase;
TAR, Total antioxidant response; NK, Natural killer; EMS, endometriosis; TNF-a, Tumor necrosis factor; IL-1b, interleukin 1b; IL-6, interleukin 6;
GV, germinal vesicle; MI, metaphase I. PA, spontaneous parthenogenetic activation; TI, telophase
Figure 1. PRISMA flow chart diagram. The effectiveness of antioxidant therapy in women with endometriosis.
Manuscript accepted for publication
Figure 2. ROBINS-1 tool for non-randomized trials
Domains:
D1: Bias due to confounding.
D2: Bias due to selection of participants.
D3: Bias in classification of interventions.
D4: Bias due to deviations from intended interventions.
D5: Bias due to missing data.
D6: Bias in measurement of outcomes.
D7: Bias in selection of the reported result.
Manuscript accepted for publication
Figure 3. RoB2 tool for randomized trials
Domains:
D1: Bias arising from the randomization process.
D2: Bias due to deviations from intended intervention.
D3: Bias due to missing outcome data.
D4: Bias in measurement of the outcome.
D5: Bias in selection of the reported result
Manuscript accepted for publication